Efficacy of aficamten in obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis.
Publication/Presentation Date
5-1-2025
Abstract
BACKGROUND: Obstructive hypertrophic cardiomyopathy (oHCM), a morbid hereditary condition, is characterized by asymmetrical intraventricular septum enlargement, obstructing blood flow from the left ventricle outflow tract (LVOT) and lowering cardiac output. Aficamten, a novel selective, oral myosin inhibitor, has been suggested to reduce myocardial hypercontractility and decrease LVOT gradient in oHCM.
METHODS: A comprehensive search was conducted through PubMed, Embase, Scopus, and Cochrane databases for relevant literature from inception up to May 2024. Six studies focusing on efficacy and safety aficamten was included. Pooled outcome estimates were reported as mean difference (MD) and 95 % CI using random effect model. Statistical heterogeneity was assessed using I
RESULTS: We found a significant change of -143.23 (pg/ml) NT-proBNP [95 % CI -564.8 to 278.4, I
CONCLUSION: We found that aficamten significantly reduced myocardial stress surrogates and functional disability parameters. The small sample sizes, diverse study designs and single-arm analysis limit our findings. More robust trials with larger sample sizes are required to establish conclusive evidence.
Volume
53
First Page
100535
Last Page
100535
ISSN
2666-6022
Published In/Presented At
Saddique, M. N., Irfan, H., Ashraf, S., Qadri, M., Javaid, H., Iftikhar, S., Haq, M. Z. U., Fatima, L., Mehmood, Q., Jha, A., Masood, S., Safiullah, M., Bhatti, M. I., Shamoon, S., & Iqbal, J. (2025). Efficacy of aficamten in obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis. American heart journal plus : cardiology research and practice, 53, 100535. https://doi.org/10.1016/j.ahjo.2025.100535
Disciplines
Medicine and Health Sciences
PubMedID
40242612
Department(s)
Fellows and Residents
Document Type
Article